Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS

Optimal time of HAART initiation is still unknown. Several studies investigating this issue showed inconsistent results. Our study investigated whether there is a clinical benefit as to treated patients (pts) by an earlier start of therapy at CD4 between 350-449c/µl, compared to the range of 250-349c/µl. An analysis was conducted on basis of the open, retrospective and prospective, multi-center and nationwide cohort of the Competence Network for HIV/AIDS. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK(Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P16 Cite this article as: Plettenberg et al.: Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS. Journal of the International AIDS Society 2010 13(Suppl 4):P16. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112938/